Type II Diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Intervention 1: The intervention group will take 100 mg CoQ10 capsules twice a day for 3 months. Intervention 2: The control group will take 100 mg placebo (edible microcrystalin celulose) capsules t
Treatment - Drugs
Placebo
The intervention group will take 100 mg CoQ10 capsules twice a day for 3 months
The control group will take 100 mg placebo (edible microcrystalin celulose) capsules twice a day for 3 months.
Sponsors
Shahid Sadoughi University of Medical Sciences and Health Services
Eligibility
Sex/Gender
All
Age
35 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1.The agreement of the patients to contribute in the trial; 2. patients that have type two diabetes for at least 5 years; 3.The patients should have neuropathy symptoms that have been recognized by a physician (The patients’ score on the Michigan score should be at least 8 and their nerve reflexes should be weak); 4.The patients should not have any other neurologic, kidney or hepatic diseases; 5.If the patients take medicine for neuropathy, the dosage of their medicine should not change during the trial; 6.If the patients have not taken a medicine at the beginning of the trial, they should not start taking it during the trial; 7.The patients should not have taken antioxidant supplements from the past 3 months. Exclusion criteria 1.If a dosage of a patient's medicine changes that patient will be excluded from the trial; 2.If a patient who has not taken any medicine for his neuropathy starts to take a medicine during the trial that patient will be excluded from the trial; 3.Pregnancy and lactation.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Michigan score. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: Michigan neuropathy screening instrument.;Hs-CRP. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: Elisa.;TAC (Total antioxidant capacity). Timepoint: before intervention, 12 weeks after intervention. Method of measurement: Elisa.;FBS (fasting blood glucose). Timepoint: before intervention, 12 weeks after intervention. Method of measurement: glucose oxidase method.;Fasting Insulin. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: Elisa.;Insulin Resistance. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: Homeostasis Model Assessment of Insulin Resistance, HOMA-IR.;Sensitivity to insulin. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: HOMA Calculator for excel ver 2.2 (diabetes trials unit university of oxford).;The secretion function of the Pancreas’s ß cells. Timepoint: before intervention, 12 weeks after intervention. Method of measurement: HOMA Calculator for excel ver 2.2 (diabetes trials unit university of oxford). | — |
Secondary
| Measure | Time frame |
|---|---|
| NCS (Nerve conduction study). Timepoint: before intervention, 12 weeks after intervention. Method of measurement: Electromyography device. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Akbari
Shahid Sadoughi University of Medical Sciences and Health Services
Outcome results
None listed